Biovie is trading 18.05% down at $1.68 after its 203-patient Phase 2 ADDRESS-LC trial failed to achieve statistical significance on any endpoint in the overall population. - Pre-specified higher-severity subgroups showed significant improvements, and safety results were favorable. - Biovie plans to advance bezisterim toward a Phase 3 confirmatory trial. - Sector weakness adds pressure, but the decline is primarily company-specific and disappointed investors.